期刊文献+

Aβ_(42)及其亚单位疫苗接种正常成年大鼠的行为学观察 被引量:8

Observation of Cognitive Behavior After Complete and Subunit of Aβ_(42) Vaccine Inoculation in Normal Adult Rats
暂未订购
导出
摘要 【目的】 探讨Aβ42及其亚单位肽疫苗接种正常成年大鼠后对其认知行为的影响?【方法】 采用固相肽合成法和肽疫苗技术制备Aβ42 N端1~15和C端36~42亚单位片段疫苗和Aβ42全肽疫苗? ①Aβ42及C端亚单位肽疫苗接种:32只SPF级成年雄性SD大鼠随机分为MAP36~42组,牛血清白蛋白组(BSA组),Aβ42组和对照组,每组8只?②Aβ42亚单位片段多联疫苗接种:同样条件的SD大鼠随机分为MAP1~15组,多联疫苗组Ⅰ,多联疫苗组Ⅱ和对照组?应用Morris水迷宫检测免疫接种后大鼠的认知行为能力?【结果】 SD大鼠接种Aβ42及其亚单位疫苗后,其平均逃避潜伏期以及平台象限的游泳距离的百分比,与对照组大鼠的比较,差异均无显著性(P >0.05)? 【结论】 Aβ42及其亚单位肽疫苗接种后对正常成年SD大鼠的认知行为无影响? Objective To investigate the behavioral variation of normal adult rats after they were inoculated by complete and subunit of Aβ42 vaccine. Methods We constructed entire peptide and subunit peptide vaccine of Aβ42 by means of Fmoc SPPS(solid phase peptide synthesis) and peptide vaccine technique. ①In the inoculation of complete and C-terminal subunit vaccine of Aβ42, 32 adult male Sprague-Dawley rats (SPF grade) were divided into MAP36~42 group, BSA group, Aβ42 group and control group (PBS group). ②In the inoculation of multivalent vaccine of Aβ42, another 32 same species of rats were also divided into MAP1~15 group, multivalent vaccine groupⅠ, multivalent vaccine groupⅡ and control group. After finishing all inoculations, the cognitive behavior of SD rats was as-sessed by Morris water maze Results Not only the average latencies but also the percentage of to-tal swimming distance in the platform quadrant showed no significant discrepancy between the experimen-tal groups and control group (P< 0.05). Conclusion There are no behavioral variation of the SD rats after they were inoculated by completer and subunit of Aβ42 vaccine.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2004年第3期208-211,共4页 Journal of Sun Yat-Sen University:Medical Sciences
基金 广东省自然科学基金重点资助项目(20013137) 中山市科技局重点攻关项目 (4209606)
关键词 Β淀粉样蛋白 亚单位肽疫苗 水迷宫 免疫接种 认知行为 阿耳茨海默病 β-Amyloid subunit vaccine morris water maze inoculation
  • 相关文献

参考文献10

  • 1Hock C, Konietzko U, Papassotiropoulos A, et al.Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease[J] . Nature Medicine, 2002, 8(11): 1270-5.
  • 2Nicoll J A R, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report[J]. Nature,2003, 9(4): 448-52.
  • 3Hock C, Konietzko U, Streffer J R, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer' s disease[J]. Neuron, 2003, 38(5): 547-54.
  • 4Schenk D. Amyloid-β immunotherapy for Alzheimer' s disease: the end of the beginning[J]. Nature Reviews,2002, 3(10): 824-8.
  • 5林贤,汪华侨,徐杰,姚志彬.Aβ_(42)及其C端亚单位疫苗接种正常SD大鼠后产生高滴度的抗Aβ_(42)抗体[J].解剖学报,2003,34(3):231-235. 被引量:22
  • 6Morris R. Developments of a water-maze procedure for studying spatial learning in the rat[J]. J Neruosci Meth,1984, 11(1): 47-60.
  • 7Mclaurin J, Cecal R, Kierstead M E, et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid residues 4-10 and inhibit cytotoxicity and fibrillogensis[J] . Nature Medicine, 2002, 8 (11):1263-9.
  • 8Jamieson G A, Maitland N J, Wilcock G K, et al. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains[J]. J Med Virol, 1991, 33(4): 224-7.
  • 9Itzhaki R F, Dobson C B, Lin W R, et al. Association of HSV1 and apolipoprotein E-varepsilon4 in Alzheimer's disease. J Neurovirol, 2001, 7(6): 570-1.
  • 10Itzhaki R F, Wozniak M A, Dobson. Inflammatory consequences: benevolent, or virulent? [J]. Neurobio Aging, 2002,23(5): 681-2.

二级参考文献12

  • 1Schenk D, Barbour R, Dunn W, et al. Innunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J].[see comments]. Nature, 1999,400 (6740): 173-177.
  • 2Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease[J]. Nature, 2000,408 (6815): 979-982.
  • 3Morgan D, Diamond DM, Gottschal PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer' s disease [J].Nature, 2000,408 (6815): 982-985.
  • 4Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease[J]. Nature Medicine,2000,6(8) :916-919.
  • 5DeMattos RB, Bales KB, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer' s disease [J]. Proc Natl Acad Sci USA, 2001,98(15): 8850-8855.
  • 6Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model[J]. Nature Neuroscience,2002,5(5) :452-457.
  • 7Schenk D. Amyloid-β immunotherapy for Alzheimer's disease:the end of the beginning[J]. Nature Reviews, 2002,3: 824-828.
  • 8Morris R. Developments of a water-maze procedure for studying spatial learning in the rat [J]. J Neurosci Meth, 1984,11(1):47-60.
  • 9Lewis J, Dickson DW, Lin WL, et al. Enhanced neurodibrillary degeneration in transgenic mice expressing mutant Tau and APP [J].Science, 2001,293 (24): 1487-1491.
  • 10Gotz J, Chen F, Dorpe JV, et al. Formation of neurofibrillary tangle in P301L Tau transgenic mice induced by Aβ42 fibrils [J]. Science, 2001,293(24): 1491-1495.

共引文献21

同被引文献32

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部